27-week study to evaluate SER-109 versus placebo to reduce recurrence of clostridium difficile infection in adults who have received treatment for recurrent CDI.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.AcceptPrivacy Policy